OSM
OSM (oncostatin M) is a secreted cytokine and growth regulator of the LIF/OSM family, which belongs to the interleukin 6 type cytokine family. It signals through gp130-containing receptor complexes to regulate cell proliferation, differentiation and cytokine production, and has the previous symbol MGC20461. Browse Assay Genie's current range of OSM research reagents below, or read on for the biology behind the target.
OSM functions as a cytokine that can use two distinct receptors. The type I OSM receptor is a heterodimer of LIFR and IL6ST (gp130), while the type II OSM receptor is a heterodimer of OSMR and IL6ST. Through these complexes, oncostatin M regulates cell proliferation, cell differentiation and cytokine production.
Mechanistically, OSM binds IL6ST/gp130 with low affinity and induces heterodimerisation with LIFR or OSMR. This activates JAK tyrosine kinases bound to the receptor intracellular domains, principally JAK1 or JAK2 and to a lesser extent TYK2. The kinases phosphorylate IL6ST and LIFR or OSMR, and the phosphorylated receptors become docking sites for recruitment and activation of STAT3. The type II receptor complex can also recruit STAT5B. In addition, it recruits SHC1 through OSMR in a JAK1-mediated, phosphotyrosine-dependent manner, so that SHC1 associates with GRB2 and activates the Ras/Raf/MAPK pathway.
The OSM gene encodes a preproprotein that is proteolytically processed to give the mature secreted protein. Alternative splicing produces multiple transcript variants, at least one of which encodes an isoform that is itself proteolytically processed. NCBI describes oncostatin M as a growth regulator that inhibits the proliferation of a number of tumour cell lines, and as a regulator of interleukin 6, granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor production in endothelial cells. The gene and the related leukaemia inhibitory factor gene both lie on chromosome 22 and may have arisen by duplication of a common ancestral gene.
OSM engages both type I (LIFR/IL6ST) and type II (OSMR/IL6ST) receptor complexes, making it a useful ligand for dissecting gp130-family signalling.
Ligand binding activates JAK1, JAK2 and TYK2, leading to STAT3 recruitment and, via the type II receptor, STAT5B engagement.
The type II receptor recruits SHC1 through OSMR, linking OSM to GRB2 association and downstream Ras/Raf/MAPK pathway activation.
OSM inhibits the proliferation of a number of tumour cell lines and regulates cell differentiation, which supports its study as a growth regulator.
OSM is a secreted cytokine that regulates cell proliferation, differentiation and cytokine production. It binds IL6ST/gp130, induces heterodimerisation with LIFR or OSMR, and activates JAK kinases and STAT3. It also regulates interleukin 6, G-CSF and GM-CSF production in endothelial cells.
The approved HGNC symbol is OSM and the full name is oncostatin M, listed in UniProt as Oncostatin-M. MGC20461 is a recorded alias. The gene is placed in the interleukin 6 type cytokine family and, per UniProt, belongs to the LIF/OSM family.
OSM and leukaemia inhibitory factor (LIF) are both members of the LIF/OSM family, and their genes are located on chromosome 22. They may have arisen by duplication of a common ancestral gene. The type I OSM receptor also contains LIFR, paired with IL6ST.
Other IL-6 family cytokines, their gp130-type receptors and the JAK/STAT signalling proteins linked to oncostatin M.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P13725; product specifications from Assay Genie datasheets.